JP2008502723A - 治療活性剤、クエン酸または共役塩基、および二酸化塩素を含む安定化された組成物 - Google Patents
治療活性剤、クエン酸または共役塩基、および二酸化塩素を含む安定化された組成物 Download PDFInfo
- Publication number
- JP2008502723A JP2008502723A JP2007527544A JP2007527544A JP2008502723A JP 2008502723 A JP2008502723 A JP 2008502723A JP 2007527544 A JP2007527544 A JP 2007527544A JP 2007527544 A JP2007527544 A JP 2007527544A JP 2008502723 A JP2008502723 A JP 2008502723A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- citric acid
- chlorine dioxide
- bimatoprost
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 title claims abstract description 105
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 title claims abstract description 75
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 239000004155 Chlorine dioxide Substances 0.000 title claims abstract description 52
- 235000019398 chlorine dioxide Nutrition 0.000 title claims abstract description 52
- 239000013543 active substance Substances 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 12
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 5
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims description 30
- 229960002470 bimatoprost Drugs 0.000 claims description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- 229960004106 citric acid Drugs 0.000 claims description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 10
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 8
- 150000001735 carboxylic acids Chemical class 0.000 claims description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 229960002303 citric acid monohydrate Drugs 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 4
- 239000004327 boric acid Substances 0.000 claims description 4
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 claims description 4
- 150000003180 prostaglandins Chemical class 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 2
- CDMADVZSLOHIFP-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 CDMADVZSLOHIFP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 125000003259 prostaglandin group Chemical group 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 10
- 239000002585 base Substances 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 239000002738 chelating agent Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- -1 alkali metal chlorites Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical class OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical group [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 3
- 229960002218 sodium chlorite Drugs 0.000 description 3
- 229910052723 transition metal Inorganic materials 0.000 description 3
- 150000003624 transition metals Chemical class 0.000 description 3
- 101000623895 Bos taurus Mucin-15 Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 229940003677 alphagan Drugs 0.000 description 2
- 229960003679 brimonidine Drugs 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910001919 chlorite Inorganic materials 0.000 description 2
- 229910052619 chlorite group Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000008217 ophthalmic excipient Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000007248 oxidative elimination reaction Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 102000015006 alpha2-adrenergic receptor activity proteins Human genes 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 150000004676 glycans Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 150000002731 mercury compounds Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Chemical group 0.000 description 1
- 239000005017 polysaccharide Chemical group 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 229950008081 unoprostone isopropyl Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (20)
- 有効量の治療活性剤、安定化二酸化塩素、ならびにクエン酸および/またはその共役塩基を含む眼科用組成物。
- 治療活性剤が硫黄原子を含む、請求項1の組成物。
- 治療活性剤がカルボン酸、カルボン酸エステル、またはカルボン酸アミドを含む、請求項1の組成物。
- プロスタグランジンまたはプロスタミドを含む、請求項1の組成物。
- ビマトプロストを含む、請求項1の組成物。
- ホウ酸塩/ホウ酸緩衝剤を含む、請求項1の組成物。
- 0.01%〜0.10%のビマトプロストを含む、請求項1の組成物。
- 0.001%〜0.10%のクエン酸および/またはその共役塩基を含む、請求項1の組成物。
- 約0.02%のクエン酸および/またはその共役塩基を含む、請求項7の組成物。
- 0.03%のビマトプロスト、0.39%の塩化ナトリウム、0.6%のホウ酸、0.045%のホウ酸ナトリウム十水和物、0.014%のクエン酸一水和物、0.5%のカルボキシメチルセルロース、および0.005%の安定化二酸化塩素を含み、塩酸または水酸化ナトリウムの添加によってpHが7.3に調節される、請求項8の組成物。
- 組成物の不適合構成要素を安定化する方法であって、有効量のクエン酸および/またはその共役塩基を前記組成物に添加することを含み、前記不適合構成要素が安定化二酸化塩素および第2の構成要素を含む方法。
- 第2の構成要素が治療活性剤である、請求項11の方法。
- 治療活性剤がプロスタグランジンまたはプロスタミドである、請求項12の方法。
- 治療活性剤がビマトプロストである、請求項13の方法。
- ビマトプロストが約0.03%の濃度を持つ、請求項14の方法。
- 眼科用組成物を保存処理する方法であって、有効量のクエン酸および/またはその共役塩基ならびに安定化二酸化塩素を前記組成物に加えることを含む方法。
- 約0.03%のビマトプロスト、約0.27%のリン酸水素ナトリウム七水和物、約0.014%のクエン酸一水和物、約0.83%の塩化ナトリウム、および約0.01%のPurite(登録商標)を含み、塩酸および/または水酸化ナトリウムの添加によってpHが7.3に調節される、請求項8の組成物。
- 本質的に、約0.03%のビマトプロスト、約0.27%のリン酸水素ナトリウム七水和物、約0.014%のクエン酸一水和物、約0.83%の塩化ナトリウム、および約0.01%のPurite(登録商標)、水、ならびにpHを7.3に調節するのに十分な量の塩酸および/または水酸化ナトリウムからなる、請求項8の組成物。
- 約0.03%のビマトプロスト、約0.27%のリン酸水素ナトリウム七水和物、約0.014%のクエン酸一水和物、約0.83%の塩化ナトリウム、および約0.01%のPurite(登録商標)、水、ならびにpHを7.3に調節するのに十分な量の塩酸および/または水酸化ナトリウムからなる、請求項8の組成物。
- 30ppm〜500ppmのPurite(登録商標)を含む、請求項8の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/865,639 | 2004-06-09 | ||
US10/865,639 US20050276867A1 (en) | 2004-06-09 | 2004-06-09 | Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative |
PCT/US2005/018026 WO2005123135A1 (en) | 2004-06-09 | 2005-05-19 | Stabilized compositions comprising a therapeutically active agent, citric acid or a conjugated base and chlorine dioxide |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008502723A true JP2008502723A (ja) | 2008-01-31 |
JP5108517B2 JP5108517B2 (ja) | 2012-12-26 |
Family
ID=34970420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007527544A Active JP5108517B2 (ja) | 2004-06-09 | 2005-05-19 | 治療活性剤、クエン酸または共役塩基、および二酸化塩素を含む安定化された組成物 |
Country Status (15)
Country | Link |
---|---|
US (4) | US20050276867A1 (ja) |
EP (1) | EP1753461B1 (ja) |
JP (1) | JP5108517B2 (ja) |
KR (1) | KR101184166B1 (ja) |
CN (1) | CN100579530C (ja) |
AT (1) | ATE374043T1 (ja) |
AU (1) | AU2005253931B2 (ja) |
BR (1) | BRPI0511923A (ja) |
CA (1) | CA2570148C (ja) |
DE (1) | DE602005002653T2 (ja) |
ES (1) | ES2289713T3 (ja) |
HK (1) | HK1104212A1 (ja) |
MX (1) | MXPA06014096A (ja) |
NZ (1) | NZ589247A (ja) |
WO (1) | WO2005123135A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012532130A (ja) * | 2009-06-30 | 2012-12-13 | アラーガン インコーポレイテッド | プロピオン酸誘導体を防腐剤として含有する製薬点眼液組成物 |
WO2013047373A1 (ja) * | 2011-09-29 | 2013-04-04 | 千寿製薬株式会社 | 亜塩素酸塩を含有する水性製剤 |
JP2014515383A (ja) * | 2011-05-27 | 2014-06-30 | レイショファーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | PGF2α類似体を含む眼科用製剤 |
JP2015500347A (ja) * | 2011-12-16 | 2015-01-05 | アラーガン インコーポレイテッドAllergan,Incorporated | ポリビニルカプロラクタム−ポリビニルアセテート−ポリエチレングリコールグラフト共重合体を含む眼用組成物 |
JP2015120730A (ja) * | 2008-07-15 | 2015-07-02 | ビーエーエスエフ コーポレーション | 非細胞毒性二酸化塩素流体 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010102078A1 (en) | 2009-03-04 | 2010-09-10 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
US7851504B2 (en) | 2005-03-16 | 2010-12-14 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
US9561178B2 (en) * | 2006-07-25 | 2017-02-07 | Allergan, Inc. | Cyclosporin compositions |
DE102009021372A1 (de) * | 2009-05-14 | 2010-11-18 | Ursapharm Arzneimittel Gmbh | Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung |
US20110136872A1 (en) * | 2009-12-09 | 2011-06-09 | Burk Robert M | Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof |
US9522153B2 (en) | 2009-12-22 | 2016-12-20 | Allergan, Inc. | Compositions and methods for lowering intraocular pressure |
CN108310442B (zh) * | 2017-01-17 | 2021-08-27 | 台北科技大学 | 眼科用组合物 |
TW202014194A (zh) | 2018-04-27 | 2020-04-16 | 美商歐樂根公司 | 抗微生物功效增強且毒性降低之亞氯酸鈉組成物 |
US20220125801A1 (en) * | 2019-03-06 | 2022-04-28 | Mankind Pharma Ltd. | Ophthalmic composition of bimatoprost |
US10881111B1 (en) | 2019-11-26 | 2021-01-05 | NEOCL Co., Ltd. | Composition for providing room temperature long-term constant-concentration chlorine dioxide solution in aqueous medium and preparation method thereof |
US11786538B2 (en) | 2019-12-11 | 2023-10-17 | Somerset Therapeutics, Llc | Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties |
US20230293541A1 (en) | 2022-03-21 | 2023-09-21 | Somerset Therapeutics, Llc | Methods of treating ophthalmic conditions with enhanced penetration compositions of bimatoprost and timolol |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2988514A (en) * | 1958-06-11 | 1961-06-13 | Olin Mathieson | Bleaching composition and method |
JPS60184002A (ja) * | 1984-03-01 | 1985-09-19 | Daiichi Seimo Kk | 赤腐れ菌又は青海苔の防除剤 |
JPH01319408A (ja) * | 1988-06-17 | 1989-12-25 | Kikuo Oikawa | 安定化二酸化塩素水溶液の製造法 |
JPH02290240A (ja) * | 1989-04-28 | 1990-11-30 | Takasugi Seiyaku Kk | 凝固状環境浄化組成物 |
JPH03219815A (ja) * | 1990-01-24 | 1991-09-27 | Dai Ichi Seiyaku Co Ltd | マコンブ種苗の赤変病防除方法 |
JPH04349104A (ja) * | 1991-05-07 | 1992-12-03 | Takasugi Seiyaku Kk | 粉末又は粒状環境浄化組成物 |
JPH05502810A (ja) * | 1990-01-05 | 1993-05-20 | アラーガン、インコーポレイテッド | レンズを消毒するための方法および組成物 |
US5736165A (en) * | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
JPH10211265A (ja) * | 1997-01-29 | 1998-08-11 | M Y Corp:Kk | 消臭・防腐・除菌作用を有する剤 |
US20020035264A1 (en) * | 2000-07-13 | 2002-03-21 | Kararli Tugrul T. | Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3278447A (en) * | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
US4689215A (en) * | 1984-07-30 | 1987-08-25 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4696811A (en) * | 1984-07-30 | 1987-09-29 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
AU4658089A (en) | 1988-11-29 | 1990-06-26 | Bio-Cide International, Inc. | Disinfectant compositions for ophthalmic devices |
IL92351A (en) | 1988-11-29 | 1994-02-27 | Allergan Inc Irvine | Optimal aqueous solutions containing stabilized chlorine acid and inorganic salt |
US5246662A (en) * | 1989-10-02 | 1993-09-21 | Allergan, Inc. | Methods for generating chlorine dioxide and compositions for disinfecting |
US5538974A (en) * | 1994-01-27 | 1996-07-23 | Senju Pharamceutical Co., Ltd. | Ophthalmic composition for lowering intraocular pressure |
WO2002072105A2 (en) * | 2001-02-21 | 2002-09-19 | Alcon, Inc. | Improved prostanoid therapies for the treatment of glaucoma |
US6982079B2 (en) * | 2002-04-26 | 2006-01-03 | Allergan, Inc. | Compositions for treating hyperemia |
-
2004
- 2004-06-09 US US10/865,639 patent/US20050276867A1/en not_active Abandoned
-
2005
- 2005-05-19 AT AT05752215T patent/ATE374043T1/de active
- 2005-05-19 CN CN200580018817A patent/CN100579530C/zh not_active Expired - Fee Related
- 2005-05-19 WO PCT/US2005/018026 patent/WO2005123135A1/en active IP Right Grant
- 2005-05-19 JP JP2007527544A patent/JP5108517B2/ja active Active
- 2005-05-19 BR BRPI0511923-5A patent/BRPI0511923A/pt not_active IP Right Cessation
- 2005-05-19 AU AU2005253931A patent/AU2005253931B2/en active Active
- 2005-05-19 DE DE602005002653T patent/DE602005002653T2/de active Active
- 2005-05-19 EP EP05752215A patent/EP1753461B1/en active Active
- 2005-05-19 CA CA2570148A patent/CA2570148C/en active Active
- 2005-05-19 MX MXPA06014096A patent/MXPA06014096A/es active IP Right Grant
- 2005-05-19 US US11/570,200 patent/US8343949B2/en active Active
- 2005-05-19 NZ NZ589247A patent/NZ589247A/en not_active IP Right Cessation
- 2005-05-19 ES ES05752215T patent/ES2289713T3/es active Active
- 2005-05-19 KR KR1020067025890A patent/KR101184166B1/ko not_active IP Right Cessation
-
2007
- 2007-08-17 HK HK07108977A patent/HK1104212A1/xx not_active IP Right Cessation
-
2012
- 2012-11-30 US US13/690,863 patent/US8691802B2/en active Active
-
2014
- 2014-04-04 US US14/245,014 patent/US20150283240A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2988514A (en) * | 1958-06-11 | 1961-06-13 | Olin Mathieson | Bleaching composition and method |
JPS60184002A (ja) * | 1984-03-01 | 1985-09-19 | Daiichi Seimo Kk | 赤腐れ菌又は青海苔の防除剤 |
JPH01319408A (ja) * | 1988-06-17 | 1989-12-25 | Kikuo Oikawa | 安定化二酸化塩素水溶液の製造法 |
JPH02290240A (ja) * | 1989-04-28 | 1990-11-30 | Takasugi Seiyaku Kk | 凝固状環境浄化組成物 |
JPH05502810A (ja) * | 1990-01-05 | 1993-05-20 | アラーガン、インコーポレイテッド | レンズを消毒するための方法および組成物 |
JPH03219815A (ja) * | 1990-01-24 | 1991-09-27 | Dai Ichi Seiyaku Co Ltd | マコンブ種苗の赤変病防除方法 |
JPH04349104A (ja) * | 1991-05-07 | 1992-12-03 | Takasugi Seiyaku Kk | 粉末又は粒状環境浄化組成物 |
US5736165A (en) * | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
JPH10211265A (ja) * | 1997-01-29 | 1998-08-11 | M Y Corp:Kk | 消臭・防腐・除菌作用を有する剤 |
US20020035264A1 (en) * | 2000-07-13 | 2002-03-21 | Kararli Tugrul T. | Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug |
JP2004528267A (ja) * | 2000-07-13 | 2004-09-16 | ファルマシア・アンド・アップジョン・カンパニー | 選択的シクロオキシゲナーゼ−2阻害性薬物の眼処方 |
Non-Patent Citations (1)
Title |
---|
JPN6011040280; WANG,B. et al: 'Experimental observation on germicidal efficacy and toxicity of chlorine dioxide disinfectant' Zhongguo Xiaoduxue Zazhi Vol.17, No.2, 2000, p.96-98 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015120730A (ja) * | 2008-07-15 | 2015-07-02 | ビーエーエスエフ コーポレーション | 非細胞毒性二酸化塩素流体 |
JP2012532130A (ja) * | 2009-06-30 | 2012-12-13 | アラーガン インコーポレイテッド | プロピオン酸誘導体を防腐剤として含有する製薬点眼液組成物 |
JP2014515383A (ja) * | 2011-05-27 | 2014-06-30 | レイショファーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | PGF2α類似体を含む眼科用製剤 |
WO2013047373A1 (ja) * | 2011-09-29 | 2013-04-04 | 千寿製薬株式会社 | 亜塩素酸塩を含有する水性製剤 |
JP2015500347A (ja) * | 2011-12-16 | 2015-01-05 | アラーガン インコーポレイテッドAllergan,Incorporated | ポリビニルカプロラクタム−ポリビニルアセテート−ポリエチレングリコールグラフト共重合体を含む眼用組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20130090387A1 (en) | 2013-04-11 |
BRPI0511923A (pt) | 2008-01-22 |
MXPA06014096A (es) | 2007-01-31 |
US8343949B2 (en) | 2013-01-01 |
JP5108517B2 (ja) | 2012-12-26 |
CA2570148C (en) | 2012-10-23 |
ES2289713T3 (es) | 2008-02-01 |
NZ589247A (en) | 2012-06-29 |
US20050276867A1 (en) | 2005-12-15 |
US20150283240A1 (en) | 2015-10-08 |
ATE374043T1 (de) | 2007-10-15 |
US20080300315A1 (en) | 2008-12-04 |
WO2005123135A1 (en) | 2005-12-29 |
WO2005123135A8 (en) | 2006-06-22 |
CN1964743A (zh) | 2007-05-16 |
US8691802B2 (en) | 2014-04-08 |
AU2005253931B2 (en) | 2011-05-19 |
CN100579530C (zh) | 2010-01-13 |
EP1753461A1 (en) | 2007-02-21 |
HK1104212A1 (en) | 2008-01-11 |
AU2005253931A1 (en) | 2005-12-29 |
CA2570148A1 (en) | 2005-12-29 |
KR20070028405A (ko) | 2007-03-12 |
DE602005002653T2 (de) | 2008-07-17 |
KR101184166B1 (ko) | 2012-09-19 |
EP1753461B1 (en) | 2007-09-26 |
DE602005002653D1 (de) | 2007-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5108517B2 (ja) | 治療活性剤、クエン酸または共役塩基、および二酸化塩素を含む安定化された組成物 | |
JP4856392B2 (ja) | 防腐剤及びこれを含有する水性組成物 | |
NO339109B1 (no) | Konserverende sammensetning for oftalmisk anvendelse | |
JP4757970B2 (ja) | 点眼剤組成物 | |
JP2002114711A (ja) | 外用剤組成物 | |
JP5922609B2 (ja) | 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性組成物 | |
WO2010119942A1 (ja) | レボカバスチン懸濁型点眼剤 | |
JP4294276B2 (ja) | 点眼剤組成物 | |
JP2011184452A (ja) | 防腐剤及びこれを含有する水性組成物 | |
JP2007269673A (ja) | 保存剤 | |
JP2007016024A (ja) | ロフルミラスト点眼液 | |
JP5111372B2 (ja) | 安定および保存化ケトチフェン眼用組成物 | |
JP4832015B2 (ja) | オキシグルタチオン含有水溶液 | |
WO2011027365A9 (en) | Ophthalmic compositions containing dorzolamide, timolol and brimonidine | |
MXPA04011777A (es) | Composicion farmaceutica. | |
US20100267824A1 (en) | Stable oxaliplatin composition for parenteral administration | |
KR20240105332A (ko) | 브리모니딘을 포함하는 안과용 조성물 | |
JP2012224629A (ja) | ペミロラストを含有する安定な水性組成物 | |
JPH0322365B2 (ja) | ||
JP2010132587A (ja) | 眼科用剤 | |
US20190224177A1 (en) | Stable liquid compositions of sodium picosulfate | |
JPH06293638A (ja) | 安定なビタミンa類点眼剤 | |
JPH05262644A (ja) | アミノ酸含有輸液の安定化方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080423 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110802 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20110829 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110907 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111102 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120301 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120601 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120903 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120927 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121005 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5108517 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151012 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |